FDA sent a warning letter , dated July 31, 2019, to Spectrum Laboratory Products, Inc. after an inspection of the company s New Brunswick, NJ facility found the site had not transferred all quality and regulatory information about its API manufacturer to its customers. The company had beenOriginal Article
You may also like
New alloys for manufacturing freeze-dryers
Navigating the Complexities of Emerging Therapy...
INTERPHEX 2025: Preventing Spills in the Manufacturing...
Agentic AI Growth Predicted, but More Than Half of...
Microsoft and SkyCell Collaborate on Pharma Supply...
Siemens Acquires Dotmatics, Extending AI Software...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.